Compare DexCom, Inc. (DXCM) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs SoFi Technologies Inc — how do they compare? DexCom, Inc. trades at $77.98 (market cap $28.06B), while SoFi Technologies Inc trades at $17.4 (market cap $22.92B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | SOFI | |
|---|---|---|
Market Cap | $28.06B | $22.92B |
Sector | Health | Financials |
52-Week High | $89.53 | $32.21 |
52-Week Low | $54.84 | $15.15 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
SOFI stock trades at $17.60, down 5.12% on the day, reflecting recent market pressures. The technical outlook is neutral with mixed signals, while fundamentals show robust revenue growth to $3.61 billion in 2025 and consistent earnings beats. Analyst sentiment is divided with a consensus price target of $22.43, but the stock faces headwinds from negative operating cash flow and high valuation multiples.
The investment case hinges on SOFI's ability to sustain top-line expansion and improve cash flow generation. Near-term catalysts include Q2 2026 earnings on July 29, where management guides for 30% revenue growth. Key risks involve persistent cash burn, competitive intensity in fintech, and sensitivity to interest rate changes. The stock offers upside to consensus targets if execution remains strong.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
